X-linked hypophosphatemia, fibroblast growth factor 23 signaling, and craniosynostosis

被引：0

作者：

Grimbly, Chelsey ^{[1
,2
]}

Graf, Daniel ^{[2
,3
]}

Ward, Leanne M. ^{[4
]}

Alexander, R. Todd ^{[1
,2
]}

机构：

[1] Univ Alberta, Dept Pediat, Edmonton Clin Hlth Acad, Edmonton, AB T6G 2R7, Canada

[2] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB T6G 2R7, Canada

[3] Univ Alberta, Dept Dent & Dent Hyg, Edmonton, AB T6G 2R7, Canada

[4] Univ Ottawa, Childrens Hosp Eastern Ontario, Fac Med, Div Endocrinol & Metab,Dept Pediat, Ottawa, ON K1H 8L1, Canada

来源：

EXPERIMENTAL BIOLOGY AND MEDICINE | 2023年 / 248卷 / 22期

关键词：

Rickets; phosphate; craniosynostosis; fibroblast growth factor 23; hypophosphatemia; X-linked hypophosphatemia; ALKALINE-PHOSPHATASE; SAGITTAL SYNOSTOSIS; FGF RECEPTOR; RICKETS; BONE; RESISTANT; PHEX; MINERALIZATION; OSTEOPONTIN; GENE;

D O I：

10.1177/15353702231222023

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

This review summarizes the current knowledge of fibroblast growth factor 23 signaling in bone and its role in the disease pathology of X-linked hypophosphatemia. Craniosynostosis is an under-recognized complication of X-linked hypophosphatemia. The clinical implications and potential cellular mechanisms invoked by increased fibroblast growth factor 23 signaling causing craniosynostosis are reviewed. Knowledge gaps are identified and provide direction for future clinical and basic science studies.

引用

页码：2175 / 2182

页数：8

共 50 条

[21] Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH)
Ruppe, Mary Denise
Zhang, Xiaoping
Imel, Erik Allen
Weber, Thomas Joseph
Klausner, Mark
Ito, Takahiro
Vergeire, Maria
Humphrey, Jeffrey
Glorieux, Francis H.
Portale, Anthony A.
Insogna, Karl
Peacock, Munro
Carpenter, Thomas O.
ENDOCRINE REVIEWS, 2014, 35 (03)
[22] Neurocranial growth attenuation in X-linked dominant hypophosphatemia
Ferguson, DJ
Witek, CA
Roy, WA
JOURNAL OF DENTAL RESEARCH, 1996, 75 : 1886 - 1886
[23] IS THE HUMORAL FACTOR OF X-LINKED HYPOPHOSPHATEMIA A BONE-DERIVED FACTOR
LAJEUNESSE, D
HAMEL, L
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 866 - 866
[24] First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia
Cheong, Hae Il
Yoo, Han-Wook
Adachi, Masanori
Tanaka, Hiroyuki
Fujiwara, Ikuma
Hasegawa, Yukihiro
Harada, Daisuke
Sugimoto, Maiko
Okada, Yosuke
Kato, Masaki
Shimazaki, Ryutaro
Ozono, Keiichi
Seino, Yoshiki
JBMR PLUS, 2019, 3 (02)
[25] X-LINKED HYPOPHOSPHATEMIA - IS IT CAUSED BY AN OSTEOBLAST-DERIVED FACTOR
LAJEUNESSE, D
MEYER, RA
HAMEL, L
JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S155 - S155
[26] Recombinant growth hormone therapy for X-linked hypophosphatemia in children
Yang, HM
Chaomin, W
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01):
[27] Stimulation of growth hormone secretion in children with X-linked hypophosphatemia
Seikaly, MG
Baum, M
PEDIATRIC NEPHROLOGY, 1995, 9 (06) : 751 - 752
[28] Recombinant growth hormone therapy for X-linked hypophosphatemia in children
Smith, Sherie
Remmington, Tracey
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (10):
[29] Effect of Burosumab on Growth Trends in Patients with X-Linked Hypophosphatemia
Carpenter, Thomas
Ward, Leanne
De Beur, Suzanne Jan
Cassinelli, Hamilton
Imel, Erik
Simmons, Jill
Ryabets-Lienhard, Anna
Li, Jerry
Chen, Eric
Ramirez, Antonio
JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 417 - 417
[30] Growth in young children with X-linked hypophosphatemia treated with burosumab
Ertl, Diana-Alexandra
Sala, Elisa
Trabado, Severine
Audrain, Christelle
Berkenou, Jugurtha
Rothenbuhler, Anya
Lambert, Anne-Sophie
Linglart, Agnes
HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 83 - 83

← 1 2 3 4 5 →